GLP-1 Receptor Agonist Market, by Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Albiglutide, and Semaglutide), by Route of Administration (Parenteral and Oral), by Application (Type 2 Diabetes Mellitus, Obesity, Liver Cirrhosis, Non-alcoholic Steatohepatitis, and Others {Others include Cardiovascular Disease and Type-1 Diabetes}), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
Select a license type that suits your business needs
Single User License
US$ 4,500
US$ 3,500
Three thousand five hundred dollars
Frequently purchased
Multi User License
US$ 7,000
US$ 5,500
Five thousand five hundred dollars
Corporate User License
US$ 10,000
US$ 7,500
Seven thousand five hundred dollars
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients